CJC-1295 + Ipamorelin Research Stack 10mg

The CJC-1295 + Ipamorelin Research Stack is a pre-formulated, precisely blended combination of two growth hormone secretagogues that act through distinct and complementary mechanisms. This research compound enables investigators to study the synergistic effects of dual-pathway GH axis activation without the compounding variability of separate reconstitution steps. **Composition and Rationale** This stack contains 5mg of CJC-1295 (Modified GRF 1-29) and 5mg of Ipamorelin, lyophilized together in a single vial. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates pituitary somatotroph cells to produce and release endogenous growth hormone. Ipamorelin, a ghrelin receptor (GHS-R1a) agonist, amplifies the GHRH signal through a parallel intracellular signaling cascade. The scientific basis for this combination lies in the convergence of two independent regulatory pathways governing GH secretion. GHRH (and its analogue CJC-1295) signals through the GHRH receptor on somatotroph cells, while ghrelin receptor agonists like ipamorelin modulate the same cells through GHS-R1a. Combined activation produces greater GH pulse amplitude than either agent alone—a phenomenon well-documented in endocrine research literature. **Research Applications** This pre-blended formulation is designed for laboratory investigation of: - Complementary GH/IGF-1 axis activation - Pulsatile GH release dynamics under dual-receptor stimulation - Lean mass and body composition endpoints - Sleep quality and recovery parameters in research models - Combined GH secretagogue pharmacokinetics **Quality Documentation** Each batch undergoes independent HPLC purity analysis (≥98% for each peptide), mass spectrometry identity confirmation, and endotoxin testing. Certificate of Analysis available upon request. Intended for laboratory research use only. Not for human or veterinary administration.